arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

RHYTHM PHARMACEUTICALS, INC.

RYTM
$115.67 ▲ +3.61 (+3.22%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
41 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
18
Health
Poor
Bearish
auto_awesome

Analytical Summary

RHYTHM PHARMACEUTICALS, INC. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $7.9B
Dividend Yield
Revenue Growth 83.8%
Op. Margin -87.1%
ROIC -23.9%
FCF / Share $-0.65
Trailing P/E
Price / Book 64.4x
FCF Yield
Debt / Equity 0.80
info Valuation on last close. End-of-day price, Aug 7, 2026.

41-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$60.11M
↑ +83.8%
Net Income Profit after all expenses
$-55.64M
↓ -12.4%
Operating Margin Operating profit as % of sales
-87.1%
↓ -6.0% 2th
FCF / Share Free cash flow per share
$-0.65
↓ -1.6%
Long-Term Debt Long-term obligations
$98.34M
↓ -2.5%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
3
Returns
5
Financial Health
39
Cash Quality
44

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 12 years · 41 quarters